Research Progress on RET Oncogene in Thyroid Carcinoma

doi:10.19586/j.2095-2341.2023.0002

Current Biotechnology ›› 2023, Vol. 13 ›› Issue (6): 895-899.DOI: 10.19586/j.2095-2341.2023.0002

• Reviews • Previous Articles Next Articles

Research Progress on RET Oncogene in Thyroid Carcinoma

Jiayuan JIAO(), Jiuge XING, Baoshan CHAI()

Pharmaceutical Research Laboratory，Shenyang Research Institute of Chemical Industry Co. ，Ltd. ，Shenyang 110021，China

Received:2023-01-10 Accepted:2023-09-21 Online:2023-11-25 Published:2023-12-12
Contact: Baoshan CHAI

RET原癌基因在甲状腺癌中的研究进展

焦佳媛(), 邢久歌, 柴宝山()

沈阳化工研究院有限公司医药研究室，沈阳 110021

通讯作者: 柴宝山
作者简介:焦佳媛E-mail: jiaojiayuan@sinochem.com；
基金资助:
沈阳化工研究院资助项目(99000029)

Abstract

Abstract:

Proto-oncogene rearranged during transfection （RET） was identified in 1985， and then， the different types of RET/PTC rearrangement of chromosomes were discovered in papillary thyroid carcinoma （PTC）. Activating point mutations in the RET proto-oncogene were discovered in both hereditary and sporadic forms of medullary thyroid carcinoma （MTC）. Different from the change of RET in PTC， the activation of RET in MTC is mainly through the activation point mutation. Thus， the different types of rearrangement activation of RET are closely related to the high incidence of thyroid cancer. Different activation mechanisms of RET will lead to different treatment strategies. In this review， we discussed the role of RET proto-oncogenes in the pathogenesis， diagnosis and prognosis of PTC and MTC， which was expected to provide reference for the thyroid carcinoma caused by RET activation.

Key words: rearranged during transfection, medullary thyroid carcinoma, papillary thyroid carcinoma, pathogenesis, diagnosis, prognosis

摘要：

原癌基因RET（rearranged during transfection）在1985年被鉴定，随后，在甲状腺乳头状癌（papillary thyroid carcinoma, PTC）中发现了不同类型的RET/PTC染色体重排。在遗传性和散发性的甲状腺髓样癌（medullary thyroid carcinoma, MTC）中发现RET点突变基因。与PTC中RET的变化存在不同，MTC中RET的活化主要通过激活点突变。RET不同类型的重排活化与甲状腺癌的高发密切相关，RET不同的活化机制需对应不同的治疗对策。讨论了RET原癌基因在甲状腺乳头状癌和甲状腺髓样癌中的致病、诊断和预后的作用，以期为RET活化引起的甲状腺癌的治疗提供理论依据。

关键词: 原癌基因重排, 甲状腺髓样癌, 甲状腺乳头状癌, 致病, 诊断, 预后

CLC Number:

Q279

Jiayuan JIAO, Jiuge XING, Baoshan CHAI. Research Progress on RET Oncogene in Thyroid Carcinoma[J]. Current Biotechnology, 2023, 13(6): 895-899.

焦佳媛, 邢久歌, 柴宝山. RET原癌基因在甲状腺癌中的研究进展[J]. 生物技术进展, 2023, 13(6): 895-899.

References 47

1	PELLEGRITI G, FRASCA F, REGALBUTO C, et al.. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors[J/OL]. J. Cancer Epidemiol., 2013, 2013: 965212[2023-02-20]. .
2	ELISEI R, PINCHERA A. Advances in the follow-up of differentiated or medullary thyroid cancer[J]. Nat. Rev. Endocrinol., 2012, 8(8): 466-475.
3	SAK S D. Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor[J]. Turk. Patoloji. Derg., 2015, 31(S1): 34-47.
4	GRIECO M, SANTORO M, BERLINGIERI M T, et al.. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas[J]. Cell, 1990, 60(4): 557-563.
5	MULLIGAN L M, KWOK J B, HEALEY C S, et al.. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A[J]. Nature, 1993, 363(6428): 458-460.
6	ENG C, SMITH D P, MULLIGAN L M, et al.. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours[J]. Hum. Mol. Genet., 1994, 3(2): 237-241.
7	TAKAHASHI M, RITZ J, COOPER G M. Activation of a novel human transforming gene, ret, by DNA rearrangement[J]. Cell, 1985, 42(2): 581-588.
8	ARIGHI E, BORRELLO M G, SARIOLA H. RET tyrosine kinase signaling in development and cancer[J]. Cytokine Growth Factor Rev., 2005, 16(4-5): 441-467.
9	ANDERS J, KJAR S, IBÁÑEZ C F. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site[J]. J. Biol. Chem., 2001, 276(38): 35808-35817.
10	FRANK-RAUE K, RONDOT S, RAUE F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC[J]. Mol. Cell. Endocrinol., 2010, 322(1-2): 2-7.
11	BALOH R H, ENOMOTO H, JOHNSON E MJR, et al.. The GDNF family ligands and receptors-implications for neural development[J]. Curr. Opin. Neurobiol., 2000, 10(1): 103-110.
12	RAUE F, FRANK-RAUE K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management[J]. Hormones, 2009, 8(1): 23-28.
13	HIROKAWA N, NODA Y, TANAKA Y, et al.. Kinesin superfamily motor proteins and intracellular transport[J]. Nat. Rev. Mol. Cell Biol., 2009, 10(10): 682-696.
14	KIMURA E T, NIKIFOROVA M N, ZHU Z, et al.. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J]. Cancer Res., 2003, 63(7): 1454-1457.
15	CIAMPI R, KNAUF J A, KERLER R, et al.. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer[J]. J. Clin. Invest., 2005, 115(1): 94-101.
16	UCHINO S, NOGUCHI S, YAMASHITA H, et al.. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type[J]. Jpn J. Cancer Res., 1999, 90(11): 1231-1237.
17	MULLIGAN L M, MARSH D J, ROBINSON B G, et al.. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the international RET mutation consortium[J]. J. Intern. Med., 1995, 238(4): 343-346.
18	HANSFORD J R, MULLIGAN L M. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis[J]. J. Med. Genet., 2000, 37(11): 817-827.
19	VITA D. Molecular biology of the MEN2 gene[J]. J. Intern. Med., 1998, 243(6): 505-508.
20	CERRATO A, DE FALCO V, SANTORO M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets[J]. J. Mol. Endocrinol., 2009, 43(4): 143-155.
21	ORIOLA J, HALPERIN I, RIVERA-FILLAT F, et al.. The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial[J]. J. Endocrinol. Invest., 2002, 25(1): 25-31.
22	CECCHERINI I, PASINI B, PACINI F, et al.. Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene[J]. Oncogene, 1997, 14(21): 2609-2612.
23	MARSH D J, LEAROYD D L, ANDREW S D, et al.. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma[J]. Clin. Endocrinol., 1996, 44(3): 249-257.
24	KATO M, IWASHITA T, AKHAND A A, et al.. Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation[J]. Antioxid. Redox Signal., 2000, 2(4): 841-849.
25	KATO M, IWASHITA T, TAKEDA K, et al.. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases[J]. Mol. Biol. Cell, 2000, 11(1): 93-101.
26	SAENKO V, ROGOUNOVITCH T, SHIMIZU-YOSHIDA Y, et al.. Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient[J]. Mutat. Res., 2003, 527(1-2): 81-90.
27	SALASSIDIS K, BRUCH J, ZITZELSBERGER H, et al.. Translocation t(10;14)(q11.2: Q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma[J]. Cancer Res., 2000, 60(11): 2786-2789.
28	CORVI R, BERGER N, BALCZON R, et al.. RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma[J]. Oncogene, 2000, 19(37): 4236-4242.
29	CIAMPI R, GIORDANO T J, WIKENHEISER-BROKAMP K, et al.. HOOK₃-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma[J]. Endocr. Relat. Cancer, 2007, 14(2): 445-452.
30	NETWORK C G A R, AGRAWAL N, AKBANI R, et al.. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3): 676-690.
31	KHAN M S, QADRI Q, MAKHDOOMI M J, et al.. RET/PTC gene rearrangements in thyroid carcinogenesis: assessment and clinico-pathological correlations[J]. Pathol. Oncol. Res., 2020, 26(1): 507-513.
32	SANTORO M, MOCCIA M, FEDERICO G, et al.. RET gene fusions in malignancies of the thyroid and other tissues[J/OL]. Genes, 2020, 11(4): 424[2023-02-20]. .
33	STAUBITZ J I, SCHAD A, SPRINGER E, et al.. Novel rearrangements involving the RET gene in papillary thyroid carcinoma[J]. Cancer Genet., 2019, 230: 13-20.
34	MARGRAF R L, CROCKETT D K, KRAUTSCHEID P M F, et al.. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations[J]. Hum. Mutat., 2009, 30(4): 548-556.
35	ELISEI R, ROMEI C, RENZINI G, et al.. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center[J]. J. Clin. Endocrinol. Metab., 2012, 97(2): 426-435.
36	BALOCH Z W, LIVOLSI V A. Fine-needle aspiration of the thyroid: today and tomorrow[J]. Best Pract. Res. Clin. Endocrinol. Metab., 2008, 22(6): 929-939.
37	COOPER D S, DOHERTY G M, HAUGEN B R, et al.. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214.
38	NIKIFOROV Y E. Molecular analysis of thyroid tumors[J]. Mod. Pathol., 2011, 24(S2): 34-43.
39	MOSES W, WENG J, SANSANO I, et al.. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy[J]. World J. Surg., 2010, 34(11): 2589-2594.
40	KIM B H, KIM I J. Recent updates on the management of medullary thyroid carcinoma[J]. Endocrinol. Metab., 2016, 31(3): 392-399.
41	KLOOS R T, ENG C, EVANS D B, et al.. Medullary thyroid cancer: management guidelines of the American Thyroid Association[J]. Thyroid, 2009, 19(6): 565-612.
42	ROMAN S, LIN R, SOSA J A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases[J]. Cancer, 2006, 107(9): 2134-2142.
43	刘方舟. 循环BRAF突变基因联合其它检测在甲状腺乳头状癌诊断及预后作用的实验研究[D]. 郑州: 郑州大学, 2010.
44	BALLERINI P, STRUSKI S, CRESSON C, et al.. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation[J]. Leukemia, 2012, 26(11): 2384-2389.
45	NIKIFOROV Y E, ROWLAND J M, BOVE K E, et al.. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children[J]. Cancer Res., 1997, 57(9): 1690-1694.
46	ROMEI C, CIAMPI R, FAVIANA P, et al.. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer[J]. Endocr. Relat. Cancer, 2008, 15(2): 511-520.
47	JARGIN S V. RET/PTC3 rearrangement in papillary thyroid carcinoma: possible marker of tumor progression[J]. Ann. Surg., 2017, 266(6): e120-e121.

[1]	Xinxiong LI, Weixuan HONG, Tianshun FENG, Junwei FANG, Hu ZHAO, Chunhong XIAO, Meiping WANG. Pancreatic Cancer Risk Stratification and Prognostic Prediction Model Based on Aging-related Gene Characteristics [J]. Current Biotechnology, 2025, 15(1): 158-169.
[2]	Enze CHENG-CHEN, Minghong JIA, Yueying LI. Research Progress of Nucleic Acid Reference Materials of Food-borne Pathogenic Bacteria [J]. Current Biotechnology, 2023, 13(2): 195-200.
[3]	Caihong WANG, Jianfei CHEN, Jiujun JU, Xuejie ZHU, Caixia WANG. The Mechanisms of PKM2 Promoting Tumor Progression [J]. Current Biotechnology, 2022, 12(3): 411-418.
[4]	Boyuan GUO, Pengxiang ZHAO, Hui WANG, Zhen WANG, Tingting YAO, Mengyu LIU, Yao Mawulikplimi ADZAVON, Fei XIE. Research Progress of Raman Spectroscopy in the Field of Dermatology [J]. Current Biotechnology, 2022, 12(1): 44-49.
[5]	Le LI, Xiaoqing YU, Qiaochu LI, Daode YU, Yan ZOU, Haibin YE, Haiyi WU, Jing DIAO. Overview of Epidemic Diseases of Salmon and Trout Cultured in China [J]. Current Biotechnology, 2021, 11(4): 462-470.
[6]	WANG Jue, HU Lili, LI Guilan, WU Na, ZHANG Yumin^*. Strategy for the Soluble Expression of the Astragalus membranaceus Pathogenesis-related Protein (AmPR-10) with Different Vectors of E. coli [J]. Curr. Biotech., 2021, 11(2): 231-237.
[7]	XUAN Qiyue¹, HAN Xue¹, FU Yingmei^1,2*. Research and Application Progress of Microbiological Diagnostic Methods for Extrapulmonary Tuberculosis [J]. Curr. Biotech., 2021, 11(1): 47-53.
[8]	GAO Haiming, ZHAO Yanyan^*. Application Progress of Next Generation and the Third Generation Sequencing Technology in Genetic Diagnosis [J]. Curr. Biotech., 2020, 10(6): 646-654.
[9]	CHEN Shuo1, GAO Jiaqi1, WANG Di2, LONG Yan2, LI Liang2, ZHANG Xiao1. DNA Tetrahedral Nanostructure and its Application Progress in Biotechnology [J]. Curr. Biotech., 2020, 10(6): 661-667.
[10]	MA Shengnan, ZHANG Xiaokang, YI Yang, ZHANG Zhao, YAO Tingting, ZHAO Qinghui, XIE Fei^*. Data Mining Analysis of Prognosis Related Genes of Glioblastoma [J]. Curr. Biotech., 2020, 10(3): 265-272.
[11]	YU Yi, WAN Chenlu, LIAO Yuxia, HE Zhendan, LI Ying. Application of Functionalized Mesoporous Silica Nanoparticles in the Diagnosis and Therapy of Malignant Tumors [J]. Curr. Biotech., 2018, 8(2): 118-123.
[12]	JIANG Hui1,2,3, LIU Yuqin1,2,3. The Epidemiological Situation, Prevention and Control of Tuberculosis Complicated with Diabetes Mellitus [J]. Curr. Biotech., 2017, 7(1): 25-29.
[13]	JIANG Hui1, CONG Xian-li2. Current Situation of Prevalence, Diagonosis and Prevention of Rabies in China [J]. journal1, 2011, 1(1): 45-49.

Research Progress on RET Oncogene in Thyroid Carcinoma

RET原癌基因在甲状腺癌中的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 47

Related Articles 13

Recommended Articles

Metrics

Comments